利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.023 秒)

    Method of quantitating genomic DNA
    1.
    发明授权
    Method of quantitating genomic DNA 失效
    定量基因组DNA的方法

    公开(公告)号：US5858658A

    公开(公告)日：1999-01-12

    申请号：US533967

    申请日：1995-09-26

    申请人： Thomas Haemmerle ,  Falko-Guenter Falkner ,  Johann Kohl ,  Michele Himmelspach ,  Friedrich Dorner

    发明人： Thomas Haemmerle ,  Falko-Guenter Falkner ,  Johann Kohl ,  Michele Himmelspach ,  Friedrich Dorner

    IPC分类号： G01N33/50 ,  C07H21/04 ,  C12N15/09 ,  C12Q1/68 ,  C12Q1/70

    CPC分类号： C12Q1/6876 ,  C12Q1/6851

    摘要： A method of quantitating genomic DNA in a sample is provided. The method comprises the steps of adding to the sample a given amount of at least one nucleic acid as an internal standard, wherein the standard nucleic acid differs from the genomic DNA to be quantified in at least one detectable characteristic; amplifying the genomic DNA and the internal standard nucleic acid by means of a nucleic acid amplification process employing primers complementary to repetitive genomic sequences; determining as a first amount the amount of amplified genomic DNA, and determining as a second amount the amount of amplified standard nucleic acid; and determining from the first and second amounts, as a third amount, the amount of genomic DNA originally contained in the sample. Kits for performing the method and products substantially free of foreign DNA as determined by the method also are provided.

    摘要翻译： 提供了一种定量样品中基因组DNA的方法。 该方法包括以下步骤：向样品中加入给定量的至少一种作为内标的核酸，其中标准核酸与待定量的至少一种可检测特征的基因组DNA不同; 通过使用与重复基因组序列互补的引物的核酸扩增方法扩增基因组DNA和内标核酸; 确定扩增的基因组DNA的量作为第一量，并将第二量确定为扩增的标准核酸的量; 并且从第一和第二量确定作为第三量，最初包含在样品中的基因组DNA的量。 还提供了通过该方法确定的用于执行基本上不含外来DNA的方法和产物的试剂盒。

    Method of quantitating nucleic acid
    2.
    发明授权
    Method of quantitating nucleic acid 失效
    定量核酸的方法

    公开(公告)号：US5789153A

    公开(公告)日：1998-08-04

    申请号：US533820

    申请日：1995-09-26

    申请人： Falko-Guenter Falkner ,  Thomas Haemmerle ,  Michele Himmelspach ,  Johann Kohl ,  Friedrich Dorner

    发明人： Falko-Guenter Falkner ,  Thomas Haemmerle ,  Michele Himmelspach ,  Johann Kohl ,  Friedrich Dorner

    IPC分类号： G01N33/58 ,  A61K39/00 ,  A61K39/12 ,  C07H21/04 ,  C12N15/09 ,  C12P21/08 ,  C12Q1/68 ,  C12Q1/70 ,  C12P19/34 ,  C07H21/02

    CPC分类号： C12Q1/701 ,  C12Q1/6851

    摘要： There is disclosed a method of quantitating nucleic acids in a sample by using nucleic acid amplification, wherein, prior to the amplification step, a given amount of a known nucleic acid molecule is added to the sample as internal standard, which standard nucleic acid molecule differs from the nucleic acid to be quantitated by at least one detectable characteristic; to obtain a high precision and good reproducibility, known amounts of at least two known nucleic acid molecules which differ from each other and from the nucleic acid to be quantitated in at least one detectable characteristic are added as an internal standard to the sample prior to nucleic acid amplification, the amounts of amplified sample and standard nucleic acids obtained are determined, and from the amounts obtained, the amount of the nucleic acid to be quantitated originally present in the sample is determined.

    摘要翻译： 公开了通过使用核酸扩增来定量样品中的核酸的方法，其中在扩增步骤之前，将给定量的已知核酸分子作为内标添加到样品中，该标准核酸分子不同 从要由至少一个可检测特征定量的核酸; 为了获得高精度和良好的再现性，将已知量的至少两种彼此不同的已知核酸分子和从至少一个可检测特征定量的核酸作为内标物加入到核酸前的样品中 酸扩增，测定所获得的扩增样品和标准核酸的量，从得到的量确定原样存在于样品中的待定量核酸的量。

    Factor X deletion mutants and analogues thereof
    4.
    发明授权
    Factor X deletion mutants and analogues thereof 有权
    因子X缺失突变体及其类似物

    公开(公告)号：US06562598B1

    公开(公告)日：2003-05-13

    申请号：US09367777

    申请日：1999-11-18

    申请人： Michele Himmelspach ,  Michael Pfleiderer ,  Falko-Guenter Falkner ,  Johann Eibl ,  Friedrich Dorner ,  Uwe Schlokat

    发明人： Michele Himmelspach ,  Michael Pfleiderer ,  Falko-Guenter Falkner ,  Johann Eibl ,  Friedrich Dorner ,  Uwe Schlokat

    IPC分类号： C12P2106

    CPC分类号： C12N9/6432 ,  A61K38/00 ,  C12Y304/21006

    摘要： Factor X&Dgr; analogues are provided, as well as pharmaceutical preparations containing such analogues and methods of preparing such analogues. The factor X&Dgr; analogues have a deletion of the amino acids Arg180 to Arg234 and a modification in the region of the amino acid sequence between Gly173 and Arg179 of the factor X amino acid sequence. Such analogues can include a processing site not normally present in factor X, thus allowing for selective conversion of the analogue to an active form. The analogues and preparations have utility in the treatment of a number of blood coagulation disorders.

    摘要翻译： 提供因子XDELTA类似物，以及含有此类类似物的药物制剂和制备此类类似物的方法。 因子XDELTA类似物具有氨基酸Arg180至Arg234的缺失和在因子X氨基酸序列的Gly173和Arg179之间的氨基酸序列区域的修饰。 这样的类似物可以包括通常不存在于因子X中的处理位点，从而允许将类似物选择性转化为活性形式。 类似物和制剂可用于治疗许多凝血障碍。

    Highly phosphorylated and sulfated recombinant factor IX
    7.
    发明授权
    Highly phosphorylated and sulfated recombinant factor IX 有权
    高度磷酸化和硫酸化重组因子IX

    公开(公告)号：US07575897B2

    公开(公告)日：2009-08-18

    申请号：US12058473

    申请日：2008-03-28

    申请人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    发明人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    IPC分类号： C12P21/06

    CPC分类号： C12N9/644 ,  A61K38/36 ,  C12Y304/21022

    摘要： The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

    摘要翻译： 本发明涉及纯化的重组凝血因子IX（rFIX）制剂，其中至少25％的制剂中的rFIX被完全磷酸化和硫酸化，表达产生所述制备的rFIX的细胞培养物，用于治疗的药物组合物 包括所述制剂的出血病症和治疗出血性疾病的方法，包括将所述制剂给予需要的患者的步骤。

    Factor X analog with an improved ability to be activated
    8.
    发明授权
    Factor X analog with an improved ability to be activated 有权
    因子X类似物具有改善的活化能力

    公开(公告)号：US06958322B1

    公开(公告)日：2005-10-25

    申请号：US09632722

    申请日：2000-08-04

    申请人： Michele Himmelspach ,  Uwe Schlokat

    发明人： Michele Himmelspach ,  Uwe Schlokat

    IPC分类号： C12N9/64 ,  C12N15/57 ,  A61K38/00

    CPC分类号： C12N9/6432 ,  C12Y304/21006

    摘要： This invention describes a factor Xa analog which has a substitution of a minimum of one of the amino acid between Glu226 and Arg234 and possibly Ile235, relative to the amino acid numbering according to FIG. 1, a preparation containing the activated form of the factor X analog, and a method for the production of these molecules.

    摘要翻译： 本发明描述了相对于根据图1的氨基酸编号，具有至少一个氨基酸在Glu226和Arg234之间以及可能的Ile235的取代的因子Xa类似物。 1，含有因子X类似物的活化形式的制剂，以及这些分子的制备方法。

    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX
    9.
    发明申请
    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX 有权
    高度磷酸化和硫化重组因子IX

    公开(公告)号：US20080176287A1

    公开(公告)日：2008-07-24

    申请号：US12058473

    申请日：2008-03-28

    申请人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    发明人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    IPC分类号： C12P21/04

    CPC分类号： C12N9/644 ,  A61K38/36 ,  C12Y304/21022

    摘要： The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

    摘要翻译： 本发明涉及纯化的重组凝血因子IX（rFIX）制剂，其中至少25％的制剂中的rFIX被完全磷酸化和硫酸化，表达产生所述制备的rFIX的细胞培养物，用于治疗的药物组合物 包括所述制剂的出血病症和治疗出血性疾病的方法，包括将所述制剂给予需要的患者的步骤。

    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX
    10.
    发明申请
    HIGHLY PHOSPHORYLATED AND SULFATED RECOMBINANT FACTOR IX 有权
    高度磷酸化和硫化重组因子IX

    公开(公告)号：US20070244036A1

    公开(公告)日：2007-10-18

    申请号：US11683362

    申请日：2007-03-07

    申请人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    发明人： Friedrich Scheiflinger ,  Ernst Boehm ,  Michele Himmelspach ,  Olaf Merkel

    IPC分类号： A61K38/36 ,  C12N5/08

    CPC分类号： C12N9/644 ,  A61K38/36 ,  C12Y304/21022

    摘要： The present invention relates to a purified recombinant blood coagulation factor IX (rFIX) preparation, wherein at least 25% of the rFIX in the preparation is fully phosphorylated and sulfated, a cell culture expressing a rFIX resulting in said preparation, a pharmaceutical composition for treating a bleeding disorder comprising said preparation, and a method for treating a bleeding disorder comprising the step of administering said preparation to a patient in need thereof.

    摘要翻译： 本发明涉及纯化的重组凝血因子IX（rFIX）制剂，其中至少25％的制剂中的rFIX被完全磷酸化和硫酸化，表达产生所述制备的rFIX的细胞培养物，用于治疗的药物组合物 包括所述制剂的出血病症和治疗出血性疾病的方法，包括将所述制剂给予需要的患者的步骤。